Papadopoulos, K. P., T. K. Owonikoko, M. L. Johnson, I. Brana, M. Gil-Martin, R. P. Perez, V. Moreno, A. K. Salama, E. Calvo, N. S. Yee, H. Safran, A. Gonzalez-Martin, R. Aljumaily, D. Mahadevan, K. K. Mohan, J. Li, E. Stankevich, I. Lowy, M. G. Fury, and J. Homsi. “Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients With Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study”. SKIN The Journal of Cutaneous Medicine, vol. 2, no. S1, Feb. 2018, p. S45, doi:10.25251/skin.2.supp.45.